Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Angiotensin-converting enzyme (ACE)2 is a carboxypeptidase that degrades angiotensin II and other peptides. In the kidney, ACE2 localization within the glomerulus and tubules is cell specific. This study was aimed to investigate the localization of ACE2 within the renal vasculature. We also studied the effect of the administration of a specific angiotensin II type 1 receptor blocker, telmisartan, on ACE2 expression in the renal vasculature. ACE2 and ACE were localized in renal arterioles using confocal microscopy and specific cell markers. Quantitative measurements of ACE2 and ACE mRNA were estimated in kidney arterioles isolated by laser capture microdissection using real-time PCR. In kidney arterioles, ACE was localized in the endothelial layer, whereas ACE2 was localized in the tunica media. In mice treated with telmisartan (2 mg·kg−1·day−1) for 2 wk, ACE2 expression was increased by immunostaining, whereas ACE expression was decreased. This was reflected in a decrease in the ACE/ACE2 ratio compared with vehicle-treated controls (0.53 ± 0.14 vs. 7.59 ± 2.72, P = 0.027, respectively). In kidney arterioles isolated by laser capture microdissection, the ACE/ACE2 mRNA ratio was also decreased compared with control mice (1.21 ± 0.31 vs. 4.63 ± 0.86, P = 0.044, respectively). In conclusion, in kidney arterioles ACE2 is preferentially localized in the tunica media, and its expression is increased after administration of the angiotensin II type 1 receptor blocker, telmisartan. Amplification of ACE2 in the renal vasculature may contribute to the therapeutic action of telmisartan by increasing angiotensin II degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“Vascular protection is critical to reduce cardiovascular and renal morbidity associated with diabetes and hypertension (12).”
BackgroundDonoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R., et al. (2000) · Circulation Research · doi:10.1161/01.res.87.5.e1 · Cited by 2,485 · cited 2×
“ACE2 degrades ANG II to ANG-(1-7) and ANG I to ANG-(1-9) (10, 17).”
BackgroundAngiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, M. A., Sarao, R., Oudit, G. Y., Yagil, C., Kozieradzki, I., Scanga, S. E., Oliveira-dos-Santos, A. J., da Costa, J., Zhang, L., Pei, Y., et al. (2002) · Nature · doi:10.1038/nature00786 · Cited by 1,733 · cited 9×
“ANG-(1-7) colocalized strongly with both PECAM-1 and with ACE (Fig.”
BackgroundResultInfluentialFerrario, C. M., Jessup, J., Chappell, M. C., Averill, D. B., Brosnihan, K. B., Tallant, E. A., Diz, D. I., & Gallagher, P. E. (2005) · Circulation · doi:10.1161/circulationaha.104.510461 · Cited by 1,565
Benson, S. C., Pershadsingh, H. A., Ho, C. I., Chittiboyina, A., Desai, P., Pravenec, M., Qi, N., Wang, J., Avery, M. A., & Kurtz, T. W. (2004) · Hypertension · doi:10.1161/01.hyp.0000123072.34629.57 · Cited by 1,073 · cited 9×
“ANG-(1-7) colocalized strongly with both PECAM-1 and with ACE (Fig.”
BackgroundResultInfluentialYe, M., Wysocki, J., William, J., Soler, M. J., Cokic, I., & Batlle, D. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006050423 · Cited by 485 · cited 4×
“Scoring of staining intensity was as follows: 1 absent/weak staining, 2 medium staining, and 3 strong staining (27, 34).”
BackgroundInfluentialSelf-citationMyocardial infarction increases ACE2 expression in rat and humans
Burrell, L. M., Risvanis, J., Kubota, E., Dean, R. G., MacDonald, P. S., Lu, S., Tikellis, C., Grant, S. L., Lew, R. A., Smith, A. I., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi114 · Cited by 423 · cited 9×
“ANG-(1-7) colocalized strongly with both PECAM-1 and with ACE (Fig.”
BackgroundResultInfluentialSantos, R. A. S., Campagnole-Santos, M. J., & Andrade, S. P. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00138-5 · Cited by 380 · cited 1×
“Moreover, ACE not only promotes the formation of ANG II, but also the degradation of ANG-(1-7) (23).”
BackgroundACE and ACE2 Activity in Diabetic Mice
Wysocki, J., Ye, M., Soler, M. J., Gurley, S. B., Xiao, H. D., Bernstein, K. E., Coffman, T. M., Chen, S., & Batlle, D. (2006) · Diabetes · doi:10.2337/db06-0033 · Cited by 339 · cited 1×
“An understanding of the regulation of these enzymes is clinically relevant in view of recent studies showing that ACE2 expression is altered in pathological conditions such as diabetes, hypertension, and cardiovascular diseases (5, 27, 28, 31, 32, 34).”
BackgroundSelf-citationAngiotensin II and the Heart: On the Intracrine Renin-Angiotensin System
De Mello, W. C., & Danser, A. H. J. (2000) · Hypertension · doi:10.1161/01.hyp.35.6.1183 · Cited by 279 · cited 13×
“THE RENIN-ANGIOTENSIN SYSTEM (RAS) plays a key role in the control of cardiovascular and renal function (8, 13, 30).”
BackgroundInfluentialOcaranza, M. P., Godoy, I., Jalil, J. E., Varas, M., Collantes, P., Pinto, M., Roman, M., Ramirez, C., Copaja, M., Diaz-Araya, G., et al. (2006) · Hypertension · doi:10.1161/01.hyp.0000237862.94083.45 · Cited by 273 · cited 1×
“ACE inhibitors such as enalapril and lisinopril increased heart ACE2 expression in a model of experimental myocardial infarction after left coronary artery ligation and in the transgenic Ren-2 rats, respectively (16, 20).”
BackgroundVascular gp91 phox : Beyond the Endothelium
Pagano, P. J. (2000) · Circulation Research · doi:10.1161/01.res.87.1.1 · Cited by 229
Ye, M., Wysocki, J., Naaz, P., Salabat, M. R., LaPointe, M. S., & Batlle, D. (2004) · Hypertension · doi:10.1161/01.hyp.0000126192.27644.76 · Cited by 221
Self-citationSoler, M. J., Wysocki, J., Ye, M., Lloveras, J., Kanwar, Y., & Batlle, D. (2007) · Kidney International · doi:10.1038/sj.ki.5002373 · Cited by 217 · cited 2×
“Scoring of staining intensity was as follows: 1 absent/weak staining, 2 medium staining, and 3 strong staining (27, 34).”
BackgroundSelf-citationIgase, M., Strawn, W. B., Gallagher, P. E., Geary, R. L., & Ferrario, C. M. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00068.2005 · Cited by 203 · cited 3×
“This effect of olmesartan on ACE2 was not observed with other antihypertensive drugs such as atenolol and hydralazine (14).”
BackgroundInfluentialRenin-angiotensin system inhibition prevents type 2 diabetes mellitus
Scheen, A. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70147-7 · Cited by 197 · cited 1×
“The mechanism whereby ANG II blockade exerts its cardiorenal protective effect is not completely understood, but it is largely ascribed to blockade of actions such as vasoconstriction and inhibition of cell proliferation and fibrosis which are mediated by the ANG II type 1 receptor (24).”
BackgroundBlendea, M. C., Jacobs, D., Stump, C. S., McFarlane, S. I., Ogrin, C., Bahtyiar, G., Stas, S., Kumar, P., Sha, Q., Ferrario, C. M., et al. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00402.2004 · Cited by 171
ACE2: A New Target for Cardiovascular Disease Therapeutics
Raizada, M. K., & Ferreira, A. J. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3180986219 · Cited by 166 · cited 1×
“The potential therapeutic effect of increased ACE2 activity has been recently recognized (2, 15, 22, 33).”
BackgroundJust the Beginning: Novel Functions for Angiotensin-Converting Enzymes
Eriksson, U., Danilczyk, U. G., & Penninger, J. M. (2002) · Current Biology · doi:10.1016/s0960-9822(02)01255-1 · Cited by 158 · cited 1×
“ACE2 degrades ANG II to ANG-(1-7) and ANG I to ANG-(1-9) (10, 17).”
BackgroundLi, N., Zimpelmann, J., Cheng, K., Wilkins, J. A., & Burns, K. D. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00144.2004 · Cited by 155 · cited 1×
“ACE2 degrades ANG II to ANG-(1-7) and ANG I to ANG-(1-9) (10, 17).”
BackgroundJessup, J. A., Gallagher, P. E., Averill, D. B., Brosnihan, K. B., Tallant, E. A., Chappell, M. C., & Ferrario, C. M. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00061.2006 · Cited by 128 · cited 1×
“ACE inhibitors such as enalapril and lisinopril increased heart ACE2 expression in a model of experimental myocardial infarction after left coronary artery ligation and in the transgenic Ren-2 rats, respectively (16, 20).”
BackgroundWhaley‐Connell, A. T., Chowdhury, N. A., Hayden, M. R., Stump, C. S., Habibi, J., Wiedmeyer, C. E., Gallagher, P. E., Tallant, E. A., Cooper, S. A., Link, C. D., et al. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00167.2006 · Cited by 125 · cited 2×
“(30) in the Ren2 transgenic rat, AT1 receptor blockade was associated with increased ACE2 expression.”
Background2 Inhibitiors of Angiotensin-Converting Enzyme
Cushman, D. W., & Ondetti, M. A. (1980) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)70157-7 · Cited by 125
Wakahara, S., Konoshita, T., Mizuno, S., Motomura, M., Aoyama, C., Makino, Y., Kato, N., Koni, I., & Miyamori, I. (2007) · Endocrinology · doi:10.1210/en.2006-1287 · Cited by 117
Schunkert, H., Ingelfinger, J. R., Hirsch, A. T., Tang, S., Litwin, S. E., Talsness, C. E., & Dzau, V. J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116020 · Cited by 92 · cited 1×
“Activation of the RAS has been widely incriminated in the pathophysiology of renal and cardiovascular diseases such as hypertension, myocardial infarction, and heart failure (21, 25).”
BackgroundDevelopmental expression of ACE2 in the SHR kidney: A role in hypertension?
Tikellis, C., Cooper, M. E., Bialkowski, K., Johnston, C. I., Burns, W. C., Lew, R. A., Smith, A. I., & Thomas, M. C. (2006) · Kidney International · doi:10.1038/sj.ki.5000428 · Cited by 91 · cited 1×
“An understanding of the regulation of these enzymes is clinically relevant in view of recent studies showing that ACE2 expression is altered in pathological conditions such as diabetes, hypertension, and cardiovascular diseases (5, 27, 28, 31, 32, 34).”
BackgroundEnalapril and Losartan Reduced Cardiac Mass and Improved Coronary Hemodynamics in SHR
Núñez, E., Hosoya, K., Sušić, D., & Frohlich, E. D. (1997) · Hypertension · doi:10.1161/01.hyp.29.1.519 · Cited by 86 · cited 1×
“ANG II type 1 receptor blockers are widely used as antihypertensive drugs that also decrease left ventricular hypertrophy and proteinuria (4, 18, 19).”
BackgroundMizuno, M., Sada, T., Kato, M., & Koike, H. (2002) · Hypertension Research · doi:10.1291/hypres.25.271 · Cited by 76 · cited 1×
“ANG II type 1 receptor blockers are widely used as antihypertensive drugs that also decrease left ventricular hypertrophy and proteinuria (4, 18, 19).”
BackgroundControl of blood pressure by the renin‐angiotensin‐aldosterone system
Hall, J. E. (1991) · Clinical Cardiology · doi:10.1002/clc.4960141802 · Cited by 69 · cited 1×
“THE RENIN-ANGIOTENSIN SYSTEM (RAS) plays a key role in the control of cardiovascular and renal function (8, 13, 30).”
BackgroundImmunolocalization of ACE2 and AT 2 Receptors in Rabbit Atherosclerotic Plaques
Zulli, A., Burrell, L. M., Widdop, R. E., Black, M. J., Buxton, B. F., & Hare, D. L. (2005) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.5c6782.2005 · Cited by 60 · cited 1×
“(35) found ACE2 in -SMA-positive cells, but this was reported in atherosclerotic plaques from thoracic aorta of male New Zealand white rabbits.”
BackgroundBATLLE, D. C., Soler, M. J., & Wysocki, J. A. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f945c2 · Cited by 39 · cited 9×
“ANG-(1-7) colocalized strongly with both PECAM-1 and with ACE (Fig.”
BackgroundResultInfluentialSelf-citationGodeny, M. D., & Sayeski, P. P. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00618.2005 · Cited by 33
Ingelfinger, J. R. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006090986 · Cited by 32 · cited 1×
“The potential therapeutic effect of increased ACE2 activity has been recently recognized (2, 15, 22, 33).”
BackgroundRenal protection: Are all antihypertensive drugs comparable?
Blake, R., Raij, L. R., & Schulman, I. H. (2007) · Current Hypertension Reports · doi:10.1007/s11906-007-0069-4 · Cited by 5 · cited 9×
“ANG-(1-7) colocalized strongly with both PECAM-1 and with ACE (Fig.”
BackgroundResultInfluential
Cited by
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.-C., Turner, A. J., Raizada, M. K., Grant, M. B., & Oudit, G. Y. (2020) · Circulation Research · doi:10.1161/circresaha.120.317015 · Cited by 1,882
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
Nishiga, M., Wang, D. W., Han, Y., Lewis, D. B., & Wu, J. C. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0413-9 · Cited by 1,409
Bourgonje, A. R., Abdulle, A. E., Timens, W., Hillebrands, J., Navis, G. J., Gordijn, S. J., Bolling, M. C., Dijkstra, G., Voors, A. A., Osterhaus, A. D., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5471 · Cited by 1,081
Sardu, C., Gambardella, J., Morelli, M. B., Wang, X., Marfella, R., & Santulli, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051417 · Cited by 592
Metadata
- Authors
- Soler, M. J., Ye, M., Wysocki, J., William, J., Lloveras, J., & Batlle, D.
- Venue
- American Journal of Physiology-Renal Physiology
- Publisher
- American Physiological Society
- Published
- 2009-02
- Volume
- 296
- Issue
- 2
- Pages
- F398-F405
- ISSN
- 1522-1466 (ISSN-L)
- 1931-857X
- OpenAlex
- W2144370633
- Cited by
- 199
- References
- 34
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.